



Charting ambitious growth plans

07 July 2010 | News





Head: Amit Chatterjee (CEO)

Business: Laboratory and process

technology provider **Start-up Year:**1991


Address: No.10, 3rd Phase, Peenya 6th Main, KIADB Industrial Area,

Bangalore-560 058, Karnataka Tel: +91-80-27700351 Fax: +91-80-27723183

Website: www.sartorius-stedim.com

Life Sciences Business (in Rs Crore)

Rs 95 Crore



Sartorius offers the widest and best integrated portfolio in the industry for manufacturing pharmaceuticals using single-use and hybrid systems Sartorius Stedim has invested about Rs 28.52 crore in India for expanding its

The Sartorius Group is an internationally-leading laboratory and process technology mechatronics segments.

The company reported sales of Rs 95 crore from its life sciences business in FY09 as

Though the downturn affected Sartorius, the company still went ahead with its ambitious growth plans and investments in making India the center of excellence for its Asian

About Rs 28.52 crore (â,¬5 mn) has been invested in India for expanding the competencies, capability and capacity to serve the group and Asian market requirements. Since the beginning of this year, the company has seen large orders for aceutical plants.

In production technology, the biopharmaceutical industry is currently witnessing a complete paradigm shift. The industry is increasingly switching from stainless steel equipment to single-use products. As a market-focused organization, Sartorius has been strategically heading and propelling developments to create a portfolio of products and a total solutions approach.

While the equipment business slowed down in line with the economic sentiments, the consumable and single-use devices saw a significant growth. The industry really promoted the membrane-based chromatography devices which saw it move from R&D through process development into commercial production in several customers in vaccine industry. The trend towards single-use fluid handling bags, connectors and more critically, the bioreactors, was quite evident as the industry looked to reduce its capital d development time.

With the best-in-class design, engineering, manufacturing, process control and application support competencies in India, the company offers the widest and best integrated portfolio in the industry for the manufacture of pharmaceuticals using single-use and hybrid systems. The company is optimistic that it would be launching highly attractive new products for the biopharmaceutical industry and R&D in 2010 as well.